Vitae Pharmaceuticals (VTAE) : Zacks Investment Research ranks Vitae Pharmaceuticals (VTAE) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 2, which indicates as a Buy.
Vitae Pharmaceuticals (VTAE) : The highest level Vitae Pharmaceuticals (VTAE) is projected to reach is $23 for the short term and the lowest estimate is at $10. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $16.6 and the possibility the share price can swing is $5.03.
Also, Major Brokerage house, JMP Securities downgrades its ratings on Vitae Pharmaceuticals (NASDAQ:VTAE). According to the latest information available, the shares are now rated Market Perform by the analysts at the agency. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on August 4, 2016.
Vitae Pharmaceuticals (NASDAQ:VTAE): The stock opened in the green at $20.85 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $20.88 and a low of $20.83 for the day. The stock did not find buyers even at the lows and closed at $20.84 recording a loss of -0.05%. 5,319,714 shares exchanged hands during the trading day. The stock had closed at $20.85 in the previous days trading.
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Companys two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimers disease. The Companys several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.